NARI / Inari Medical: Targeting Underpenetrated $5.8 Billion Thromboembolism Market

Inari Medical's (NARI) third-quarter results benefit from strong product adoption and geographical performances. more_horizontal

IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat a more_horizontal

Inari Medical, Inc. (NASDAQ:NARI ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants John Hsu - VP, IR Drew Hykes - Pr more_horizontal

IRVINE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat a more_horizontal

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a co more_horizontal

The consensus price target hints at a 36.4% upside potential for Inari Medical, Inc. (NARI). While empirical research shows that this sought-after met more_horizontal

Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers. more_horizontal

The medical device maker boosted its revenue and returned to the black on net income. Management said it benefited from the launch of two new products more_horizontal